interesting article, however posting an article that supports your point of view is standard confirmation bias. The clinical value of chemokine receptor antagonists is evident from the successful application of drugs like plerixafor, maraviroc, and mogamulizumab, which have shown therapeutic efficacy in their respective indications despite the issue of tolerance
And honestly, i dont understand the point. Just because something may become less effective overtime does that mean its not worth taking at all? The scientific advisory board would disagree![]()
- Forums
- ASX - By Stock
- DXB
- Dimerix (ASX: DXB) Discussion Thread
Dimerix (ASX: DXB) Discussion Thread, page-425
-
- There are more pages in this discussion • 216 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
|
|||||
Last
53.0¢ |
Change
0.020(3.92%) |
Mkt cap ! $291.6M |
Open | High | Low | Value | Volume |
51.0¢ | 53.8¢ | 51.0¢ | $782.0K | 1.490M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 6408 | 53.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
53.5¢ | 35657 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 6408 | 0.530 |
2 | 48000 | 0.525 |
6 | 113118 | 0.520 |
4 | 57872 | 0.515 |
14 | 177420 | 0.510 |
Price($) | Vol. | No. |
---|---|---|
0.535 | 35657 | 1 |
0.540 | 75830 | 5 |
0.545 | 232172 | 7 |
0.550 | 73893 | 6 |
0.555 | 120000 | 2 |
Last trade - 16.10pm 01/07/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online